Literature DB >> 30601139

Molecular imaging of fibrosis: recent advances and future directions.

Sydney B Montesi1, Pauline Désogère2,3,4, Bryan C Fuchs5, Peter Caravan2,3,4.   

Abstract

Fibrosis, the progressive accumulation of connective tissue that occurs in response to injury, causes irreparable organ damage and may result in organ failure. The few available antifibrotic treatments modify the rate of fibrosis progression, but there are no available treatments to reverse established fibrosis. Thus, more effective therapies are urgently needed. Molecular imaging is a promising biomedical methodology that enables noninvasive visualization of cellular and subcellular processes. It provides a unique means to monitor and quantify dysregulated molecular fibrotic pathways in a noninvasive manner. Molecular imaging could be used for early detection, disease staging, and prognostication, as well as for assessing disease activity and treatment response. As fibrotic diseases are often molecularly heterogeneous, molecular imaging of a specific pathway could be used for patient stratification and cohort enrichment with the goal of improving clinical trial design and feasibility and increasing the ability to detect a definitive outcome for new therapies. Here we review currently available molecular imaging probes for detecting fibrosis and fibrogenesis, the active formation of new fibrous tissue, and their application to models of fibrosis across organ systems and fibrotic processes. We provide our opinion as to the potential roles of molecular imaging in human fibrotic diseases.

Entities:  

Mesh:

Year:  2019        PMID: 30601139      PMCID: PMC6307954          DOI: 10.1172/JCI122132

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  104 in total

1.  Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.

Authors:  Barry S Shea; Sarah F Brooks; Benjamin A Fontaine; Jerold Chun; Andrew D Luster; Andrew M Tager
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

Review 2.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 3.  Fibrosis--a common pathway to organ injury and failure.

Authors:  Don C Rockey; P Darwin Bell; Joseph A Hill
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

4.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

5.  Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.

Authors:  Flavia V Castelino; Jon Seiders; Gretchen Bain; Sarah F Brooks; Christopher D King; James S Swaney; Daniel S Lorrain; Jerold Chun; Andrew D Luster; Andrew M Tager
Journal:  Arthritis Rheum       Date:  2011-05

6.  Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.

Authors:  Sven H Hausner; Danielle DiCara; Jan Marik; John F Marshall; Julie L Sutcliffe
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

7.  Molecular Magnetic Resonance Imaging of Lung Fibrogenesis with an Oxyamine-Based Probe.

Authors:  Philip A Waghorn; Chloe M Jones; Nicholas J Rotile; Steffi K Koerner; Diego S Ferreira; Howard H Chen; Clemens K Probst; Andrew M Tager; Peter Caravan
Journal:  Angew Chem Int Ed Engl       Date:  2017-07-13       Impact factor: 15.336

8.  Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging.

Authors:  Jason M Tarkin; Francis R Joshi; Nicholas R Evans; Mohammed M Chowdhury; Nichola L Figg; Aarti V Shah; Lakshi T Starks; Abel Martin-Garrido; Roido Manavaki; Emma Yu; Rhoda E Kuc; Luigi Grassi; Roman Kreuzhuber; Myrto A Kostadima; Mattia Frontini; Peter J Kirkpatrick; Patrick A Coughlin; Deepa Gopalan; Tim D Fryer; John R Buscombe; Ashley M Groves; Willem H Ouwehand; Martin R Bennett; Elizabeth A Warburton; Anthony P Davenport; James H F Rudd
Journal:  J Am Coll Cardiol       Date:  2017-04-11       Impact factor: 24.094

9.  Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Authors:  Derek J Erstad; Christian T Farrar; Sarani Ghoshal; Ricard Masia; Diego S Ferreira; Yin-Ching Iris Chen; Ji-Kyung Choi; Lan Wei; Phillip A Waghorn; Nicholas J Rotile; Chuantao Tu; Katherine A Graham-O'Regan; Mozhdeh Sojoodi; Shen Li; Yang Li; Guogiang Wang; Kathleen E Corey; Yat Sun Or; Lijuan Jiang; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs
Journal:  Hepatol Commun       Date:  2018-05-21

10.  A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.

Authors:  Furong Ye; Xueming Wu; Eun-Kee Jeong; Zhanjun Jia; Tianxin Yang; Denis Parker; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

View more
  31 in total

1.  Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies.

Authors:  Sydney B Montesi; David Izquierdo-Garcia; Pauline Désogère; Eric Abston; Lloyd L Liang; Subba Digumarthy; Ravi Seethamraju; Michael Lanuti; Peter Caravan; Ciprian Catana
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

Review 2.  Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Sydney B Montesi; Peter Caravan
Journal:  Curr Rheumatol Rep       Date:  2019-04-25       Impact factor: 4.592

Review 3.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

Review 4.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

Review 5.  Challenges in IBD Research: Novel Technologies.

Authors:  Manish Dhyani; Nitin Joshi; Willem A Bemelman; Michael S Gee; Vijay Yajnik; André D'Hoore; Giovanni Traverso; Mark Donowitz; Gustavo Mostoslavsky; Timothy K Lu; Neil Lineberry; Heiko G Niessen; Dan Peer; Jonathan Braun; Conor P Delaney; Marla C Dubinsky; Ashley N Guillory; Maria Pereira; Nataly Shtraizent; Gerard Honig; David Brent Polk; Andrés Hurtado-Lorenzo; Jeffrey M Karp; Fabrizio Michelassi
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

6.  68Ga-NODAGA-Indole: An Allysine-Reactive Positron Emission Tomography Probe for Molecular Imaging of Pulmonary Fibrogenesis.

Authors:  Jessica Wahsner; Pauline Désogère; Eric Abston; Katherine A Graham-O'Regan; Junfeng Wang; Nicholas J Rotile; Markus D Schirmer; Diêgo Dos Santos Ferreira; Jingyi Sui; Bryan C Fuchs; Michael Lanuti; Peter Caravan
Journal:  J Am Chem Soc       Date:  2019-03-27       Impact factor: 15.419

Review 7.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

8.  Imaging and targeting LOX-mediated tissue remodeling with a reactive collagen peptide.

Authors:  Matthew R Aronoff; Paul Hiebert; Nina B Hentzen; Sabine Werner; Helma Wennemers
Journal:  Nat Chem Biol       Date:  2021-07-12       Impact factor: 15.040

9.  Toward Molecular Imaging of Intestinal Pathology.

Authors:  Mariane Le Fur; Iris Y Zhou; Onofrio Catalano; Peter Caravan
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

10.  Magnetic resonance imaging accurately tracks kidney pathology and heterogeneity in the transition from acute kidney injury to chronic kidney disease.

Authors:  Jennifer R Charlton; Yanzhe Xu; Teresa Wu; Kim A deRonde; Jillian L Hughes; Shourik Dutta; Gavin T Oxley; Aleksandra Cwiek; Helen P Cathro; Nathan P Charlton; Mark R Conaway; Edwin J Baldelomar; Neda Parvin; Kevin M Bennett
Journal:  Kidney Int       Date:  2020-09-08       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.